title: Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry.
abstract: The outcome for children with deep vein thrombosis (DVT) and pulmonary embolism (PE) is unknown. An understanding of morbidity and mortality of DVT/PE is crucial to the development of rational treatment protocols. The Canadian Childhood Thrombophilia Registry has followed 405 children aged 1 mo to 18 y with DVT/PE for a mean of 2.86 y (range, 2 wk to 6 y) to assess outcome. The all-cause mortality was 65 of 405 children (16%). Mortality directly attributable to DVT/PE occurred in nine children (2.2%), all of whom had central venous line-associated thrombosis. Morbidity was substantial, with 33 children (8.1%) having recurrent thrombosis, and 50 children (12.4%) having postphlebitic syndrome. Recurrent thrombosis and postphlebitic syndrome were more common in older children, although deaths occurred equally in all age groups. The incidence of recurrent thrombosis and postphlebitic syndrome are likely underestimated because of difficulties in diagnosis, especially in younger children. The significant mortality and morbidity found in our study supports the need for international multicenter randomized clinical trials to determine optimal prophylactic and therapeutic treatment for children with DVT/PE.
authors.affiliation: Canadian Childhood Thrombophilia Program, Hamilton Civic Hospital Research Centre, Hamilton, Ontario, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Monagle
authors.forename: M
authors.initials: M
authors.lastname: Adams
authors.forename: M
authors.initials: M
authors.lastname: Mahoney
authors.forename: K
authors.initials: K
authors.lastname: Ali
authors.forename: D
authors.initials: D
authors.lastname: Barnard
authors.forename: M
authors.initials: M
authors.lastname: Bernstein
authors.forename: L
authors.initials: L
authors.lastname: Brisson
authors.forename: M
authors.initials: M
authors.lastname: David
authors.forename: S
authors.initials: S
authors.lastname: Desai
authors.forename: M F
authors.initials: MF
authors.lastname: Scully
authors.forename: J
authors.initials: J
authors.lastname: Halton
authors.forename: S
authors.initials: S
authors.lastname: Israels
authors.forename: L
authors.initials: L
authors.lastname: Jardine
authors.forename: M
authors.initials: M
authors.lastname: Leaker
authors.forename: P
authors.initials: P
authors.lastname: McCusker
authors.forename: M
authors.initials: M
authors.lastname: Silva
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.forename: R
authors.initials: R
authors.lastname: Anderson
authors.forename: M
authors.initials: M
authors.lastname: Andrew
authors.forename: M P
authors.initials: MP
authors.lastname: Massicotte
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012008:Recurrence; D012042:Registries; D013923:Thromboembolism / Q000209:etiology / Q000401:mortality / Q000503:physiopathology*; D016896:Treatment Outcome